MIRA Pharmaceuticals shares are trading higher after the company announced a recent pre-clinical study in rats demonstrated that Ketamir-2 produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals shares rise following positive pre-clinical study results showing Ketamir-2 significantly reverses neuropathic pain in rats.
August 26, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' stock is trading higher due to positive pre-clinical study results for Ketamir-2, which showed significant reversal of neuropathic pain in rats.
The announcement of successful pre-clinical results for Ketamir-2 is likely to boost investor confidence in MIRA Pharmaceuticals, leading to a positive impact on its stock price. The study's results suggest potential for future development and commercialization, which is critical for a pharmaceutical company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100